scholarly journals Half-life modeling of basic fibroblast growth factor released from growth factor-eluting polyelectrolyte multilayers

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ivan Ding ◽  
Amy M. Peterson

AbstractGrowth factor-eluting polymer systems have been widely reported to improve cell and tissue outcomes; however, measurements of actual growth factor concentration in cell culture conditions are limited. The problem is compounded by a lack of knowledge of growth factor half-lives, which impedes efforts to determine real-time growth factor concentrations. In this work, the half-life of basic fibroblast growth factor (FGF2) was determined using enzyme linked immunosorbent assay (ELISA). FGF2 release from polyelectrolyte multilayers (PEMs) was measured and the data was fit to a simple degradation model, allowing for the determination of FGF2 concentrations between 2 and 4 days of culture time. After the first hour, the FGF2 concentration for PEMs assembled at pH = 4 ranged from 2.67 ng/mL to 5.76 ng/mL, while for PEMs assembled at pH = 5, the concentration ranged from 0.62 ng/mL to 2.12 ng/mL. CRL-2352 fibroblasts were cultured on PEMs assembled at pH = 4 and pH = 5. After 2 days, the FGF2-eluting PEM conditions showed improved cell count and spreading. After 4 days, only the pH = 4 assembly condition had higher cells counts, while the PEM assembled at pH = 5 and PEM with no FGF2 showed increased spreading. Overall, the half-life model and cell culture study provide optimal concentration ranges for fibroblast proliferation and a framework for understanding how temporal FGF2 concentration may affect other cell types.

2020 ◽  
Author(s):  
Ivan Ding ◽  
Amy Peterson

Abstract Growth factor-eluting polymer systems have been widely reported to improve cell and tissue outcomes; however, measurements of actual growth factor concentration in cell culture conditions are limited. The problem is compounded by a lack of knowledge of growth factor half-lives, which impedes efforts to determine real-time growth factor concentrations. In this work, the half-life of basic fibroblast growth factor (FGF2) was determined using enzyme linked immunosorbent assay (ELISA). FGF2 release from polyelectrolyte multilayers (PEMs) was measured and the data was fit to a simple degradation model, allowing for the determination of FGF2 concentrations between 2 days and 4 days of culture time. After the first hour, the FGF2 concentration for PEMs assembled at pH=4 ranged from 2.67 ng/mL to 5.76 ng/mL, while for PEMs assembled at pH=5, the concentration ranged from 0.62 ng/mL to 2.12 ng/mL. CRL-2352 fibroblasts were cultured on PEMs assembled at pH=4 and pH=5. After 2 days, the FGF2-eluting PEM conditions showed improved cell count and spreading. After 4 days, only the pH=4 assembly condition had higher cells counts, while the PEM assembled at pH=5 and PEM with no FGF2 showed increased spreading. Overall, the half-life model and cell culture study provide optimal concentration ranges for fibroblast proliferation and a framework for understanding how temporal FGF2 concentration may affect other cell types.


2019 ◽  
Vol 55 (18) ◽  
pp. 2672-2675 ◽  
Author(s):  
Ryosuke Ueki ◽  
Saki Atsuta ◽  
Ayaka Ueki ◽  
Junya Hoshiyama ◽  
Jingyue Li ◽  
...  

A 76-mer single-stranded DNA acts as functional mimic of basic fibroblast growth factor (bFGF), one of the essential factors for stem cell culture.


2005 ◽  
Vol 48 (1) ◽  
pp. 57-58 ◽  
Author(s):  
Lukáš Smolej ◽  
Ctirad Andrýs ◽  
Vladimír Maisnar ◽  
Luděk Pour ◽  
Jaroslav Malý

Angiogenesis plays a major role in the development and progression of haematological malignancies. In our study we measured plasma concentrations of key angiogenic activators vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) using comercially available sandwich enzyme-linked immunosorbent assay (ELISA) in 37 patients with lymphoid malignancies and 20 healthy donors. We found a statistically significant increase in bFGF concentrations in patients with B-cell chronic lymphocytic leukemia (B-CLL, n=18) compared to the control group (median 118.8 vs. 9.3 pg/ml, p<0.001). However, we didn’t find any significant difference in VEGF concentrations between B-CLL patients and the control group. There was also no significant increase in bFGF or VEGF in patients with multiple myeloma (n=7) and non-Hodgkin’s lymphoma (n=12). Our pilot study shows that measurement of angiogenic activators in plasma is a feasible and reproducible method of angiogenesis assessment. Larger studies are needed for correlation between serum and plasma concentrations and detailed statistical evaluation including the impact on patients’ survival.


2004 ◽  
Vol 6 (2) ◽  
pp. 88-93 ◽  
Author(s):  
Matthew M. Hanasono ◽  
Joanne Lum ◽  
Lisa A. Carroll ◽  
Anthony A. Mikulec ◽  
R. James Koch

2011 ◽  
Vol 26 (5) ◽  
pp. 191-196 ◽  
Author(s):  
X J Yang ◽  
Y H Jiang ◽  
J W Zheng ◽  
L Hong ◽  
Q Zhou ◽  
...  

Objective To investigate the role of serum basic fibroblast growth factor (bFGF), estradiol (E2) and urine bFGF in differentiating infantile haemangiomas from vascular malformations. Method Between October 2007 and January 2009, 97 patients with haemangiomas and 25 patients with vascular malformations who had not been treated previously were included in this prospective study. Forty-eight patients with cleft lip and/or palate were selected as controls. The age of all subjects ranged from 1 to 30 months. The serum and urine levels of bFGF were determined by enzyme-linked immunosorbent assay (ELISA). The serum levels of E2 were examined via radioimmunoassay. All data were analysed with SPSS 11.5 software package. Results The concentration of serum and urine bFGF was significantly different among the three groups (haemangiomas, vascular malformations and controls) ( P = 0.027, P = 0.001). Significantly different urine bFGF levels were found in patients with proliferating and involuting haemangiomas ( P = 0.04). The serum E2 levels were significantly higher in patients with haemangiomas than vascular malformations ( P = 0.001) and controls ( P = 0.001). Conclusion Serum bFGF and E2 as well as urine bFGF can be used to supplement the clinical diagnosis of congenital vascular anomalies. Urine bFGF combined with serum E2 may be the most potential markers for diagnosing haemangiomas and determining the proliferating stage of haemangiomas.


Sign in / Sign up

Export Citation Format

Share Document